Jankovic J - Search Results

1

Galpern WR, Coffey CS, Albanese A, Cheung K, Comella CL, Ecklund DJ, Fahn S, Jankovic J, Kieburtz K, Lang AE, McDermott MP, Shefner JM, Teller JK, Thompson JL, Yeatts SD, Jinnah HA. Galpern WR, et al. Among authors: jankovic j. Neurotherapeutics. 2014 Jan;11(1):117-27. doi: 10.1007/s13311-013-0221-6. Neurotherapeutics. 2014. PMID: 24282121 Free PMC article. Review.

2

Benefits and risks of pharmacological treatments for essential tremor.

Lyons KE, Pahwa R, Comella CL, Eisa MS, Elble RJ, Fahn S, Jankovic J, Juncos JL, Koller WC, Ondo WG, Sethi KD, Stern MB, Tanner CM, Tintner R, Watts RL. Lyons KE, et al. Among authors: jankovic j. Drug Saf. 2003;26(7):461-81. doi: 10.2165/00002018-200326070-00003. Drug Saf. 2003. PMID: 12735785 Review.

3

Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study.

Truong D, Duane DD, Jankovic J, Singer C, Seeberger LC, Comella CL, Lew MF, Rodnitzky RL, Danisi FO, Sutton JP, Charles PD, Hauser RA, Sheean GL. Truong D, et al. Among authors: jankovic j. Mov Disord. 2005 Jul;20(7):783-91. doi: 10.1002/mds.20403. Mov Disord. 2005. PMID: 15736159 Clinical Trial.

4

Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay.

Brin MF, Comella CL, Jankovic J, Lai F, Naumann M; CD-017 BoNTA Study Group. Brin MF, et al. Among authors: jankovic j. Mov Disord. 2008 Jul 30;23(10):1353-60. doi: 10.1002/mds.22157. Mov Disord. 2008. PMID: 18546321 Clinical Trial.

5

Unique properties of botulinum toxins.

Jankovic J, Albanese A, Hallett M. Jankovic J, et al. Toxicon. 2009 Oct;54(5):675. doi: 10.1016/j.toxicon.2009.01.007. Epub 2009 Jan 23. Toxicon. 2009. PMID: 19470348 No abstract available.

6

Reply: Based on the available randomized trial patients should say no to glutathione for Parkinson's disease.

Okun MS, Lang A, Jankovic J. Okun MS, et al. Among authors: jankovic j. Mov Disord. 2010 May 15;25(7):961-2; author reply 962-3. doi: 10.1002/mds.23021. Mov Disord. 2010. PMID: 20461816 Clinical Trial. No abstract available.

7

Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial.

Jankovic J, Comella C, Hanschmann A, Grafe S. Jankovic J, et al. Mov Disord. 2011 Jul;26(8):1521-8. doi: 10.1002/mds.23658. Epub 2011 Apr 22. Mov Disord. 2011. PMID: 21520284 Clinical Trial.

8

Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia.

Comella CL, Jankovic J, Truong DD, Hanschmann A, Grafe S; U.S. XEOMIN Cervical Dystonia Study Group. Comella CL, et al. Among authors: jankovic j. J Neurol Sci. 2011 Sep 15;308(1-2):103-9. doi: 10.1016/j.jns.2011.05.041. Epub 2011 Jul 18. J Neurol Sci. 2011. PMID: 21764407 Clinical Trial.

9

Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE).

Jankovic J, Adler CH, Charles PD, Comella C, Stacy M, Schwartz M, Sutch SM, Brin MF, Papapetropoulos S. Jankovic J, et al. BMC Neurol. 2011 Nov 4;11:140. doi: 10.1186/1471-2377-11-140. BMC Neurol. 2011. PMID: 22054223 Free PMC article.

10

Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1.

Elm JJ; NINDS NET-PD Investigators. Elm JJ, et al. Mov Disord. 2012 Oct;27(12):1513-21. doi: 10.1002/mds.25175. Mov Disord. 2012. PMID: 23079770 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,233 results

Search Page